liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH
University of Groningen, Netherlands.
University of Groningen, Netherlands.
University of Groningen, Netherlands.
Linköping University, Department of Social and Welfare Studies, Division of Health, Activity and Care. Linköping University, Faculty of Medicine and Health Sciences.
Show others and affiliations
2015 (English)In: European Journal of Heart Failure, ISSN 1388-9842, E-ISSN 1879-0844, Vol. 17, no 12, 1271-1282 p.Article in journal (Refereed) PublishedText
Abstract [en]

AimTraditionally, risk stratification in heart failure (HF) emphasizes assessment of high risk. We aimed to determine if biomarkers could identify patients with HF at low risk for death or HF rehospitalization. Methods and resultsThis analysis was a substudy of The Coordinating Study Evaluating Outcomes of Advising and Counselling in Heart Failure (COACH) trial. Enrolment of HF patients occurred before discharge. We defined low risk as the absence of death and/or HF rehospitalizations at 180days. We tested a diverse group of 29 biomarkers on top of a clinical risk model, with and without N-terminal pro-B-type natriuretic peptide (NT-proBNP), and defined the low risk biomarker cut-off at the 10th percentile associated with high positive predictive value. The best performing biomarkers together with NT-proBNP and cardiac troponin I (cTnI) were re-evaluated in a validation cohort of 285 HF patients. Of 592 eligible COACH patients, the mean (SD) age was 71 (+/- 11) years and median (IQR) NT-proBNP was 2521 (1301-5634) pg/mL. Logistic regression analysis showed that only galectin-3, fully adjusted, was significantly associated with the absence of events at 180days (OR 8.1, 95% confidence interval 1.06-50.0, P=0.039). Galectin-3, showed incremental value when added to the clinical risk model without NT-proBNP (increase in area under the curve from 0.712 to 0.745, P=0.04). However, no biomarker showed significant improvement by net reclassification improvement on top of the clinical risk model, with or without NT-proBNP. We confirmed our results regarding galectin-3, NT-proBNP, and cTnI in the independent validation cohort. Conclusion We describe the value of various biomarkers to define low risk, and demonstrate that galectin-3 identifies HF patients at (very) low risk for 30-day and 180-day mortality and HF rehospitalizations after an episode of acute HF. Such patients might be safely discharged.

Place, publisher, year, edition, pages
WILEY-BLACKWELL , 2015. Vol. 17, no 12, 1271-1282 p.
Keyword [en]
Heart failure; Prognosis; Biomarker; N-terminal pro-B-type natriuretic peptide; Galectin-3; Risk stratification
National Category
URN: urn:nbn:se:liu:diva-123762DOI: 10.1002/ejhf.407ISI: 000366415700012PubMedID: 26466857OAI: diva2:892971
Available from: 2016-01-11 Created: 2016-01-11 Last updated: 2016-01-11

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jaarsma, Tiny
By organisation
Division of Health, Activity and CareFaculty of Medicine and Health Sciences
In the same journal
European Journal of Heart Failure

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 263 hits
ReferencesLink to record
Permanent link

Direct link